Clinical trial
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer: Search of…
NCT00251888 · ARCAGY/ GINECO GROUP, Other · Completed
Key facts
| NCT number | NCT00251888 |
|---|---|
| Title | CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto |
| Official title | Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus. |
| Lead sponsor | ARCAGY/ GINECO GROUP, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cervix Cancer |
| Intervention type | Drug |
| Interventions | campto (irinotecan), cisplatin (cisplatyl) |
| Enrollment | 15 |
| Start date | Nov 1, 2002 |
| Completion | Nov 1, 2005 |
| First posted | Nov 11, 2005 |
| Last update posted | Jan 25, 2017 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: